Cellular experiments show RACK1 and TRIM21 regulate ferroptosis and iron homeostasis, suggesting a therapy resistance mechanism.
Evasion of cell death drives tumor recurrence and metastasis, yet pan-cancer mechanisms of ferroptosis remain limited. We treated multiple tumor cell lines with ferroptosis inducers or anticancer agents and utilized post-translational modification proteomics including ubiquitination, acetylation, and phosphorylation during ferroptosis. We identify a significant increase in K280 ubiquitination of the ribosomal protein RACK1. Further pan-cancer cellular experiments suggest that RACK1 may suppress ferroptosis by regulating iron export via FPN1. Immunoprecipitation coupled with liquid chromatography-mass spectrometry reveals RACK1 interactions with CD98 and TRIM21. Ferroptosis inducers promote RACK1 K280 ubiquitination via TRIM21, and mechanistic studies confirm that TRIM21-mediated RACK1 ubiquitination affects cellular iron homeostasis. These findings indicate that, beyond the canonical GPX4 pathway, the xCT/CD98 complex can inhibit ferroptosis via the TRIM21/RACK1/FPN1 axis. Targeting RACK1 offers a potential therapeutic strategy to sensitize tumors to ferroptosis and overcome therapy resistance across multiple cancer types and in people with cancer.
No takes yet. Share an insight, caveat, or question.
Ju et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: